Biotech companies are increasing research into antibiotics, which large drugmakers are less frequently pursuing because of a lack of revenue opportunities, as strains of drug-resistant bacteria begin to emerge. One such company is Optimer Pharmaceuticals, which expects to get FDA approval by the end of the month for Dificid, an antibiotic against stomach infection.

Full Story:

Related Summaries